Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07271147
Recruiting Not applicable

Effects of taVNS Combined With Dexmedetomidine on POVN

NCT07271147 · tracked via the Priya Life Science China tracker
Sponsor
Affiliated Hospital of Nantong University
Phase
Not applicable
Started
2025-12-07
Last updated
2026-09-29

Condition(s) studied

Postoperative Nausea and Vomiting

Investigational drug(s) / intervention(s)

Transcutaneous Auricular Vagus Nerve StimulatorDexmedetomidine →

Transcutaneous Auricular Vagus Nerve Stimulator: Intervention Timing of Transcutaneous Auricular Vagus Nerve Stimulator: The intervention will begin 30 minutes before anesthesia induction and continue until the end of the surgery, terminating after the removal of the endotracheal tube in the PACU. The stimulation parameters are set as follows: frequency 25 Hz, pulse width 200 μs, 30 seconds on / 30 seconds off, with the current intensity set to the maximum amplitude the patient can tolerate (just below the pain threshold).

Dexmedetomidine: Dexmedetomidine was administered intravenously by infusion pump (0.5 μg/kg over 10 minutes, followed by continuous infusion at 0.4 μg/kg/h) in combination with taVNS (initiated 30 minutes before anesthesia induction and terminated after tracheal tube removal in the PACU upon the conclusion of the surgery).

Study summary

To explore the effects and possible mechanisms of dexmedetomidine combined with taVNS on the incidence of postoperative nausea and vomiting in female patients undergoing laparoscopic surgery

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Women aged 18 to 65; * Elective laparoscopic surgery under general anesthesia; * Classified as American Society of Anesthesiologists (ASA) physical status I to II; * Capable of understanding the study procedures and various assessment scales and able to effectively communicate with the researchers; * Willing to participate in the study and provide written informed consent. Exclusion Criteria: * Patients with ASA anesthesia classification ≥ III; * Poorly controlled hypertension, atrioventricular block ≥ second degree, obesity (BMI \> 30 kg/m²); * Pregnant or breastfeeding; * Known allergy to drugs used in the study protocol, history of traumatic brain injury, history of gastrointestinal surgery; * Liver or kidney dysfunction (liver enzymes or creatinine ≥ 1.5 times the normal value), alcoholism or drug abuse, mental illness, use of antiemetics, opioids, psychoactive drugs, or corticosteroids within 24 hours before surgery; * Patients with implanted stimulators (such as pacemakers, implantable vagus nerve stimulators, deep brain stimulators, spinal cord stimulators, etc.), cochlear implants, or metal implants (except in dental cases); * Skin lesions or dermatological diseases at the site of electrical stimulation; * Preoperative heart rate \< 50 bpm or the presence of sinoatrial node disease or second-degree or higher atrioventricular block; * Patients unable to cooperate with assessments; * Patients participating in other clinical trials.

Primary outcome measure(s)

  • Incidence of Postoperative PONV — The first 24 hours postoperatively
    Patients who experience at least one episode of nausea, vomiting, or retching, or any combination of these, within the first 24 hours after surgery are considered to have PONV.

Trial sites (1)

FacilityCityRegionStatus
Affiliated hospital of Nantong University Nantong Jiangsu Recruiting

More Affiliated Hospital of Nantong University trials in China

A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy Recruiting
Autologous Bone Marrow Mesenchymal Stem Cell Therapy for Ischemic Stroke Starting soon
Study of Sivelestat Sodium in OPCABG Recruiting
Wearable Devices Empowering Active Health Initiatives for High-Risk Stroke Populations Recruiting
TS Triage of HR-HPV Positive Population and Its Accuracy Study Active, not recruiting

Other trials for the same condition

A Randomized Controlled Trial Comparing the Effects of Different Anesthetic Sedatives on PONV in Laparoscopic Cholecystectomy Active, not recruiting
Association Between Preoperative Metformin Exposure and Postoperative Nausea and Vomiting in Patients Undergoing General Anesthesia Recruiting
Dexamethasone Palmitate for PONV After Open Surgery Recruiting
Dexamethasone Palmitate for PONV After Craniotomy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07271147 on ClinicalTrials.gov ↗ ← All trials in China